Revelation Biosciences Stock Forecast
NASDAQ: REVBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
REVB analyst consensus
Consensus (1 analysts)
none
Avg. price target
$17.75+2235.83%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 1 Wall Street analyst covering Revelation Biosciences (2026-10-09), 1 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $17.75, with a high estimate of $19.50 and a low estimate of $16.00. The average target implies upside of 2235.8% from the current price of $0.7599.
The spread between the highest and lowest targets is 21.9%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for REVB.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 1 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $16.00 | +2005.54% |
| Average target | $17.75 | +2235.83% |
| High target | $19.50 | +2466.13% |